{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:31:55Z","timestamp":1776493915247,"version":"3.51.2"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ejps.2019.104957","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T23:03:57Z","timestamp":1560467037000},"page":"104957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Novel insights into the chemistry of an old medicine: A general degradative pathway for penicillins from a piperacillin\/tazobactam stability study"],"prefix":"10.1016","volume":"136","author":[{"given":"Angelo","family":"Viola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Ferrazzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Cerisoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4202-1136","authenticated-orcid":false,"given":"Alessandra","family":"Tolomelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Cabri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2019.104957_bb0005","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2165\/00003495-199447030-00008","article-title":"Piperacillin\/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential","volume":"47","author":"Bryson","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2019.104957_bb0010","series-title":"The Chemistry of Penicillin","first-page":"535","author":"Clarke","year":"1949"},{"key":"10.1016\/j.ejps.2019.104957_bb0015","first-page":"4226","article-title":"Zinc content of commercial diluents widely used in drug admixtures prepared for intravenous infusion","volume":"11","author":"Desai","year":"2007","journal-title":"Int. J. Pharm. Compd."},{"issue":"2","key":"10.1016\/j.ejps.2019.104957_bb0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2147\/TCRM.S2564","article-title":"Zosyn (piperacillin\/tazobactam) reformulation: expanded compatibility and coadministration with lactated Ringer's solutions and selected aminoglycosides","volume":"4","author":"Desai","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ejps.2019.104957_bb0025","first-page":"1684","article-title":"Degradation of \u03b2-lactam antibiotics","volume":"87","author":"Deshpande","year":"2004","journal-title":"Curr. Sci."},{"key":"10.1016\/j.ejps.2019.104957_bb0030","author":"Drugs.com database for consumers and healthcare professionals"},{"key":"10.1016\/j.ejps.2019.104957_bb0035","series-title":"Particulate Contamination: Subvisible Particles","first-page":"253","author":"European Pharmacopeia","year":"2004"},{"key":"10.1016\/j.ejps.2019.104957_bb0040","author":"FDA"},{"key":"10.1016\/j.ejps.2019.104957_bb0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14787210.5.3.365","article-title":"Piperacillin-tazobactam: a \u03b2-lactam\/\u03b2-lactamase inhibitor combination","volume":"6","author":"Gin","year":"2007","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.ejps.2019.104957_bb0050","series-title":"Method for Preparing Piperacillin Impurity C","author":"Gong","year":"2014"},{"key":"10.1016\/j.ejps.2019.104957_bb0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.abb.2016.04.010","article-title":"The biological inorganic chemistry of zinc","volume":"611","author":"Krezel","year":"2016","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejps.2019.104957_bb0060","doi-asserted-by":"crossref","first-page":"37649","DOI":"10.1039\/C4RA07894B","article-title":"Selective ion pair recognition of citrate and zinc ions in water by ratiometric luminescence signaling","volume":"4","author":"McMahona","year":"2014","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejps.2019.104957_bb0065","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1248\/yakushi1947.97.10_1071","article-title":"Studies on \u03b2-lactam antibiotics for medicinal purpose. VI. Studies on the metabolism of 6-[D (\u2212)-\u03b1-(4-Ethyl-2, 3-dioxo-1-piperazinecarboxamido) phenylacetamido] penicillanic acid (T-1220)","volume":"97","author":"Saikawa","year":"1977","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.ejps.2019.104957_bb0070","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1248\/yakushi1947.97.9_995","article-title":"Studies on \u03b2-lactam antibiotics for medicinal purpose. IV. Stability of 6-[D (\u2212)-\u03b1-(4-ethyl-2, 3-dioxo-1-piperazinecarboxamido) phenylacetamido] penicillanic acid (T-1220) in aqueous solution and body fluid","volume":"97","author":"Saikawa","year":"1977","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.ejps.2019.104957_bb0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0162-0134(83)85001-6","article-title":"Crystal structure of zinc citrate","volume":"18","author":"Swanson","year":"1983","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejps.2019.104957_bb0080","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1248\/yakushi1947.97.10_1064","article-title":"Studies on \u03b2-lactam antibiotics for medicinal purpose. V. Structure of degradation products of 6-[D (\u2212)-\u03b1-(4-ethyl-2, 3-dioxo-1-piperazinecarboxamido) phenylacetamido] penicillanic acid (T-1220) in aqueous solution","volume":"97","author":"Takano","year":"1977","journal-title":"Yakugaku Zasshi"},{"issue":"Supplement 2","key":"10.1016\/j.ejps.2019.104957_bb0085","first-page":"788","article-title":"Particulate matter in injections","volume":"USP 30","author":"United States Pharmacopeia","year":"2007"},{"key":"10.1016\/j.ejps.2019.104957_bb0090","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1021\/cr020057z","article-title":"Mode of action of bi- and trinuclear zinc hydrolases and their synthetic analogues","volume":"105","author":"Weston","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejps.2019.104957_bb0095","series-title":"Zosyn\u00ae (Piperacillin\/Tazobactam For Injection USP [Glass Vials]) United States Prescribing Information and Wyeth Pharmaceuticals. 2007 Zosyn\u00ae (Piperacillin\/Tazobactam For Injection USP [Galaxy\u00ae Bags]) United States Prescribing Information","author":"Wyeth Pharmaceuticals","year":"2007"},{"key":"10.1016\/j.ejps.2019.104957_bb0100","author":"Wyeth Pharmaceuticals"},{"key":"10.1016\/j.ejps.2019.104957_bb0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0378-5173(82)90179-X","article-title":"Stability kinetics of piperacillin in aqueous solutions","volume":"11","author":"Yamana","year":"1982","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejps.2019.104957_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116769","article-title":"Clinical outcomes with alternative dosing strategies for piperacillin\/tazobactam: a systematic review and meta-analysis","volume":"10","author":"Yang","year":"2015","journal-title":"PLoSONE"},{"issue":"79","key":"10.1016\/j.ejps.2019.104957_bb0115","first-page":"1","article-title":"Piperacillin concentration in relation to therapeutic range in critically ill patients \u2013 a prospective observational study","volume":"20","author":"Zander","year":"2016","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejps.2019.104957_bb0120","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/jps.2600770418","article-title":"pH and medium-dependent degradation of piperacillin during susceptibility tests on antipseudomonal activity","volume":"77","author":"Zhi","year":"1988","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719302209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719302209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T06:37:08Z","timestamp":1562913428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098719302209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":24,"alternative-id":["S0928098719302209"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.104957","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel insights into the chemistry of an old medicine: A general degradative pathway for penicillins from a piperacillin\/tazobactam stability study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.104957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104957"}}